Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study
- 作者：Tsukasa Uno ; Norio Yasui-Furukori ; Mikiko Shimizu ; Kazunobu Sugawara and Tomonori Tateishi
- 关键词：Rabeprazole ; Rabeprazole thioether ; HPLC
- 刊名：Journal of Chromatography B ; Analytical Technologies in the Biomedical and Life Sciences
- 出版年：2005
- 期刊代码：124_15700232
- 类别：ch
- 出版时间：2005
- 卷：824
- 期：1-2
- 页码：238-243
- 文件大小：136 K
摘要
A new sensitive column-switching high-performance liquid chromatographic (HPLC) method with ultraviolet detection was developed for the simultaneous determination of rabeprazole, a proton pump inhibitor, and its active metabolite, rabeprazole thioether in human plasma. Rabeprazole, its thioether metabolite and 5-methyl-2-[{4-(3-methoxypropoxy)-3-methyl pyridin-2-yl} methyl sulfinyl]-1H-benzimidazole, as an internal standard were extracted from 1 ml of plasma using diethyl ether–dichloromethane (9:1, v/v) mixture and the extract was injected into a column I (TSK-PW precolumn, 10 μm, 35 mm × 4.6 mm I.D.) for clean-up and column II (C18 Grand ODS-80TM TS analytical column, 5 μm, 250 mm × 4.6 mm I.D.) for separation. The peak was detected with an ultraviolet detector set at a wavelength of 288 nm, and the total time for chromatographic separation was 
25 min. Mean absolute recoveries were 78.0 and 88.3%for rabeprazole and rabeprazole thioether, respectively. Intra- and inter-day coefficient variations were less than 6.5 and 4.5%for rabeprazole, 3.6 and 5.3%for rabeprazole thioether, respectively, at the different concentration ranges. The validated concentration ranges of this method were 1–1000 ng/ml for rabeprazole and 3–500 ng/ml for rabeprazole thioether. The limits of quantification were 1 ng/ml for rabeprazole and 3 ng/ml for rabeprazole thioether. The method was suitable for therapeutic drug monitoring and was applied to pharmacokinetic study in human volunteers.
25 min. Mean absolute recoveries were 78.0 and 88.3%for rabeprazole and rabeprazole thioether, respectively. Intra- and inter-day coefficient variations were less than 6.5 and 4.5%for rabeprazole, 3.6 and 5.3%for rabeprazole thioether, respectively, at the different concentration ranges. The validated concentration ranges of this method were 1–1000 ng/ml for rabeprazole and 3–500 ng/ml for rabeprazole thioether. The limits of quantification were 1 ng/ml for rabeprazole and 3 ng/ml for rabeprazole thioether. The method was suitable for therapeutic drug monitoring and was applied to pharmacokinetic study in human volunteers.